Stockscreener 앱 받기
16.78
4.77%
-0.84
시간 외 거래:
16.78
전일 마감가:
$17.62
열려 있는:
$17.6
하루 거래량:
819.73K
Relative Volume:
0.88
시가총액:
$1.11B
수익:
순이익/손실:
$-137.95M
주가수익비율:
-6.6519
EPS:
-2.5226
순현금흐름:
$-107.11M
1주 성능:
-4.11%
1개월 성능:
-23.73%
6개월 성능:
-29.88%
1년 성능:
-10.17%
1일 변동 폭
$16.69
$17.78
1주일 범위
$16.69
$17.99
52주 변동 폭
$13.70
$30.99
Bicara Therapeutics Inc Stock (BCAX) Company Profile
명칭
Bicara Therapeutics Inc
전화
617-468-4219
주소
116 HUNTINGTON AVENUE SUITE 703, BOSTON
Compare BCAX vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
16.78 | 1.11B | 0 | -137.95M | -107.11M | -2.5226 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-08-19 | 개시 | BMO Capital Markets | Outperform |
| 2026-05-11 | 개시 | Guggenheim | Buy |
| 2026-03-25 | 개시 | BofA Securities | Buy |
| 2026-01-29 | 개시 | Citizens JMP | Mkt Perform |
| 2026-01-08 | 개시 | BTIG Research | Buy |
| 2025-12-18 | 개시 | Mizuho | Neutral |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2025-05-23 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2025-04-17 | 개시 | Wells Fargo | Underweight |
| 2025-02-06 | 개시 | Wedbush | Outperform |
| 2024-12-06 | 개시 | H.C. Wainwright | Buy |
| 2024-11-05 | 개시 | Rodman & Renshaw | Buy |
| 2024-10-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-10-08 | 개시 | Morgan Stanley | Overweight |
| 2024-10-08 | 개시 | Stifel | Buy |
| 2024-10-08 | 개시 | TD Cowen | Buy |
모두보기
Bicara Therapeutics Inc 주식(BCAX)의 최신 뉴스
T. Rowe Price lists 2.8 million shares in Bicara Therapeutics (BCAX) ownership amendment. - Stock Titan
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo! Finance Canada
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
LB Pharmaceuticals Inc (LBRX) Stock Price & News - Syfe
Bicara Therapeutics Inc.Common Stock (Nasdaq:BCAX) Detailed Stock Data - The Chronicle-Journal
Cantor Fitzgerald reiterates Overweight on Bicara stock By Investing.com - Investing.com Australia
Bicara Therapeutics' President Ryan Cohlhepp Reports Stock Option Exercise and Share Sales in Form 4 Filing - Kalkine Media
Bicara interim CEO sells 17,500 shares after option exercise | BCAX Insider Trading - Stock Titan
Cantor Fitzgerald reiterates Overweight on Bicara stock By Investing.com - Investing.com Nigeria
Cantor Fitzgerald reiterates Overweight on Bicara stock By Investing.com - Investing.com India
Cantor Fitzgerald reiterates Overweight on Bicara stock By Investing.com - Investing.com UK
Cantor Fitzgerald reiterates Overweight on Bicara stock - Investing.com
JonesTrading Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $30 - moomoo.com
New Bicara (NASDAQ: BCAX) share sale planned after July and August deals - Stock Titan
BCAX Form 4 FilingsBicara Therapeutics Inc. SEC Form 4 - Stock Titan
BCAX Form 4 FilingsBicara Therapeutics Inc. SEC Form 4 - Stock Titan
BCAX 424B FilingsBicara Therapeutics Inc. SEC 424B - Stock Titan
BCAX 8-K FilingsBicara Therapeutics Inc. SEC 8-K - Stock Titan
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Bicara Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Moomoo
Boston biotech Bicara signs sublease for Wayfair space - The Business Journals
Bicara (BCAX) Financial Results: Reported EPS Tops Expectations in the Latest Session; Share Move: The Stock Records a 0.50% Decrease in the Current UpdateDividend Cut Risk - vinanet.vn
How Bicara’s Leadership Overhaul and CEO Succession Plan Could Shape Bicara Therapeutics (BCAX) Investors - webull.com
Citizens reiterates Bicara Therapeutics stock rating on trial progress - Investing.com
Citizens reiterates Bicara Therapeutics stock rating on trial progress By Investing.com - Investing.com Canada
Citizens reiterates Bicara Therapeutics stock rating on trial progress - Investing.com
Jennifer Larson Net Worth (2026) - GuruFocus
Bicara Therapeutics (NASDAQ:BCAX) Raised to "Strong-Buy" at BMO Capital Markets - MarketBeat
BMO Capital Initiates Bicara Therapeutics at Outperform - Moomoo
Bicara Therapeutics Initiated at Outperform by BMO Capital - Moomoo
Bicara Therapeutics Inc. (BCAX) Stock Price, News, Quote & History - Yahoo Finance
BICARA THERAPEUTICS INC : BMO INITIATES COVERAGE WITH OUTPERFORM RATING; PRICE TARGET $35 - Bitget
Can Bicara (BCAX) Commercialize Ficera? Breakthrough 3-Year Data Faces Execution Risk in C-Suite Overhaul - Yahoo Finance
BMO starts Bicara Therapeutics stock at Outperform on cancer drug potential - Investing.com India
BMO starts Bicara Therapeutics stock at Outperform on cancer drug potential - Investing.com Canada
BMO starts Bicara Therapeutics stock at Outperform on cancer drug potential - Investing.com
BMO Capital Initiates Bicara Therapeutics at Outperform - marketscreener.com
Bicara Therapeutics Inc. (NASDAQ:BCAX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Bicara Therapeutics (BCAX) Is Down 13.5% After Leadership Overhaul And ESOP Shelf FilingHas The Bull Case Changed? - Sahm
SCS Capital Management LLC Purchases New Shares in Bicara Therapeutics Inc. $BCAX - MarketBeat
BCAX Stock Price and Chart — NASDAQ:BCAX - TradingView
Bicara Therapeutics (BCAX) Is Down 13.5% After Leadership Overhaul And ESOP Shelf FilingHas The Bull Case Changed? - webull.com
Walleye Capital LLC Makes New $10.49 Million Investment in Bicara Therapeutics Inc. $BCAX - MarketBeat
Bicara Therapeutics (BCAX) awards 285,000 stock options to CFO Jennifer Larson - Stock Titan
Bicara Therapeutics (BCAX) CFO Jennifer Larson submits initial Form 3 - Stock Titan
Bicara Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Bicara Therapeutics Inc (BCAX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Bicara Therapeutics Inc 주식 (BCAX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Cohlhepp Ryan | President, COO & Interim CEO |
Sep 08 '26 |
Sale |
22.90 |
17,500 |
400,716 |
181,641 |
| Hyep Ivan | Officer |
Sep 08 '26 |
Proposed Sale |
22.64 |
12,500 |
283,000 |
0 |
| Cohlhepp Ryan | Officer |
Sep 08 '26 |
Proposed Sale |
22.64 |
17,500 |
396,200 |
0 |
| Hyep Ivan | Chief Financial Officer |
Aug 10 '26 |
Option Exercise |
3.79 |
12,500 |
47,372 |
142,355 |
| Hyep Ivan | Chief Financial Officer |
Aug 10 '26 |
Sale |
27.97 |
12,500 |
349,591 |
129,855 |
| Mazumdar Claire | Chief Executive Officer |
Aug 10 '26 |
Option Exercise |
3.79 |
10,000 |
37,898 |
372,152 |
| Mazumdar Claire | Chief Executive Officer |
Aug 10 '26 |
Sale |
27.98 |
10,000 |
279,750 |
362,152 |
| Cohlhepp Ryan | President and COO |
Aug 10 '26 |
Option Exercise |
3.79 |
18,750 |
71,059 |
200,391 |
| Cohlhepp Ryan | President and COO |
Aug 10 '26 |
Sale |
27.98 |
18,750 |
524,533 |
181,641 |
| Hyep Ivan | Officer |
Aug 10 '26 |
Proposed Sale |
27.83 |
12,500 |
347,875 |
0 |
0.00%
4.18%
자본화:
|
볼륨(24시간):